# Junta clínica — PT-pseudo_723f490ff7ce (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_723f490ff7ce",
  "pid": "PT-pseudo_723f490ff7ce",
  "task": 1,
  "psa": 3.7,
  "age": 69,
  "months": 2,
  "pirads": "2",
  "psad": 0.07,
  "psav": 0.77,
  "psap": 3.0,
  "vol": 60.0,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.60122794,
  "medhx": "Hypertension, Benign prostatic hyperplasia",
  "meds": "amlodipine, valsartan, tamsulosin",
  "notes": "PSA 3.7 ng/mL. PI-RADS 2. PSAD 0.07. Prostate volume 60 mL. csPCa 0.60.",
  "pmhx": [
    "Hypertension",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "63 kg",
    "height": "166 cm",
    "bmi": "22.9",
    "bp": "129/81 mmHg",
    "hr": "68 bpm",
    "smoking": "Non-smoker",
    "last_dental": "3 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "16 Jan 2025",
  "enc_ref": "Dr. K. Bakker (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Progressive PSA elevation necessitates this consultation alongside an upcoming multiparametric MRI."
    },
    {
      "s": "History",
      "t": "Employed as a hospital porter and residing independently, the 69-year-old patient first entered clinical evaluation three years ago due to urinary complaints, at which point his PSA measured 1.5 ng/mL. Subsequent testing revealed a steady upward trend, now reaching 3.7 ng/mL, while his lower urinary tract symptoms stay mild, quantified by an IPSS score of 5. Pharmacological management includes tamsulosin for benign prostatic hyperplasia, complemented by amlodipine and valsartan for hypertension, currently maintaining a blood pressure of 129/81 mmHg. Alcohol consumption is limited to 3 units weekly, and physical activity consists of chair-based exercises due to mobility constraints. Following his divorce, his former spouse remains his primary contact, assisting with administrative tasks. A long-standing hearing impairment leads him to request written summaries for all consultations. Unrelated to his urological assessment, he recently visited a podiatrist for routine foot care and underwent a standard chest radiograph during a general health screening last month. He explicitly denies bone pain, haematuria, or unexplained weight loss, noting that his daily routine remains stable despite his marital status change."
    },
    {
      "s": "Physical examination",
      "t": "DRE reveals a symmetrically enlarged gland with smooth, rubbery consistency and absent asymmetry or nodularity. General assessment shows a well-nourished individual in no acute distress, featuring clear lung fields and a regular cardiac rhythm. Peripheral pulses are fully intact, with no evidence of peripheral oedema."
    }
  ],
  "occupation": "hospital porter",
  "marital": "Divorced",
  "living": "Lives alone",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Podiatry — routine foot care",
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "3 units / week",
  "exercise": "Limited mobility — chair-based exercises only",
  "ipss": "IPSS score: 5/35 (mild LUTS)",
  "admin": "Hard of hearing — speak clearly; prefers written summaries.",
  "mri_hospital": "Amsterdam UMC (location VUmc)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_723f490ff7ce
Task: 1

Encounter: Urology - outpatient on 16 Jan 2025.
Referrer: Dr. K. Bakker (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 69-year-old male
  - PSA: 3.7 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.07 ng/mL²
  - PSA velocity: 0.77 ng/mL/yr
  - Prior PSA: 3.0 ng/mL
  - Prostate volume: 60.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.60122794 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, Benign prostatic hyperplasia
  - Current medication: amlodipine, valsartan, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 3.7 ng/mL. PI-RADS 2. PSAD 0.07. Prostate volume 60 mL. csPCa 0.60.

Vitals: weight 63 kg, height 166 cm, BMI 22.9, BP 129/81 mmHg, HR 68 bpm. Smoking: Non-smoker.

Chief complaint: Progressive PSA elevation necessitates this consultation alongside an upcoming multiparametric MRI.

History: Employed as a hospital porter and residing independently, the 69-year-old patient first entered clinical evaluation three years ago due to urinary complaints, at which point his PSA measured 1.5 ng/mL. Subsequent testing revealed a steady upward trend, now reaching 3.7 ng/mL, while his lower urinary tract symptoms stay mild, quantified by an IPSS score of 5. Pharmacological management includes tamsulosin for benign prostatic hyperplasia, complemented by amlodipine and valsartan for hypertension, currently maintaining a blood pressure of 129/81 mmHg. Alcohol consumption is limited to 3 units weekly, and physical activity consists of chair-based exercises due to mobility constraints. Following his divorce, his former spouse remains his primary contact, assisting with administrative tasks. A long-standing hearing impairment leads him to request written summaries for all consultations. Unrelated to his urological assessment, he recently visited a podiatrist for routine foot care and underwent a standard chest radiograph during a general health screening last month. He explicitly denies bone pain, haematuria, or unexplained weight loss, noting that his daily routine remains stable despite his marital status change.

Physical examination: DRE reveals a symmetrically enlarged gland with smooth, rubbery consistency and absent asymmetry or nodularity. General assessment shows a well-nourished individual in no acute distress, featuring clear lung fields and a regular cardiac rhythm. Peripheral pulses are fully intact, with no evidence of peripheral oedema.

Patient info: hospital porter; Divorced; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 3 units / week; exercise Limited mobility — chair-based exercises only; IPSS score: 5/35 (mild LUTS).

Recent other appointments: Podiatry — routine foot care; Radiology — chest X-ray (routine).
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.28
  uncertainty  +/- 0.15 epistemic (95% band 0.00-0.58); among patients I cannot tell apart the outcome was 0.86 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers DEFER.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 24 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.41: PI-RADS 2, PSA 5.0, PSAD 0.1, age 77, DRE Normal -> DEFER (clear). He wrote: "older patient with non-elevated, stable PSA. some comorbidity limits expected survival. MRI without significant lesions. Low risk of higher risk prostate cancer -> no bi…"
  2. distance 2.57: PI-RADS 2, PSA 9.8, PSAD 0.073, age 54, DRE Normal -> DEFER (clear). He wrote: "Young increases importance of longterm risk assessment. BPH, low PSAd, benign MRI, no family history increases confidence to avoid biopsy at this point."
  3. distance 3.38: PI-RADS 2, PSA 9.9, PSAD 0.19, age 48, DRE Normal -> DEFER (clear). He wrote: "No biopsy for PIRADS 2 unless PSA keeps rising"

PRECEDENT: DEFER (weighted vote 0.00 for biopsy). Distance-weighted precedent is strong here (0.92 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 24 labelled traces in this situation (None prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines link the PI-RADS score to the decision for biopsy. "A PI-RADS threshold of $\ge 3$ is used to trigger biopsy [135, 226, 264, 375]." This suggests that a PI-RADS score of 2 may not automatically mandate a biopsy based on this threshold alone.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert-Structured's suggestion of no biopsy is tempered by the cohort criterion which specifically matches the reading urologist in 24 of 24 cases where the patient had a PI-RADS 3 or higher lesion. The guideline suggests that a PI-RADS 2 may not trigger a biopsy, which aligns with the cohort's finding that deferral is appropriate in this specific situation.

WHAT WE STILL NEED
The guideline requires establishing the PSA density to guide the decision. The panel shows the PSA density is $0.07 \text{ ng/mL}^2$. The guideline suggests omitting biopsy when MRI is negative (PI-RADS $\le 2$), clinical suspicion of PCa is low, and PSA density is $< 0.20 \text{ ng/mL/cc}$ and no family history is present. The patient's PSA density of $0.07 \text{ ng/mL}^2$ is below this threshold.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the low PI-RADS score and low PSA density, combined with the cohort data, are sufficient to defer biopsy despite the rising PSA.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the identified lesion?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend beyond the headline number?
  previous_notes (get_previous_notes) -> What is the management context regarding the prior biopsy status, number of sessions, and surveillance plan?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the specific finding in the radiology_report regarding lesion size and zone?
  Q2. What is the specific trend in the psa_trend beyond the headline value?
  Q3. What is the management context regarding the prior biopsy status, number of sessions, and surveillance plan from the previous_notes?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Amsterdam UMC (VUmc) | Radiology | 15 January 2025
What is the lesion size and zone of the identified lesion? The report notes "An 8 mm nodule within the right mid-transition zone exhibits T2 hyperintensity without diffusion restriction."
psa_trend
The serial PSA value trend beyond the headline value is: {"date": "Jan 2023", "val": 2.2}, {"date": "Sep 2023", "val": 2.6}, {"date": "May 2024", "val": 3.1}, {"date": "Jan 2025", "val": 3.7}
previous_notes
What is the management context regarding the prior biopsy status, number of sessions, and surveillance plan from the previous_notes? The notes indicate "Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)" and the context was a referral for mpMRI evaluation.

WHAT I DID NOT OPEN
nothing

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
The PSA trend shows a clear upward trajectory from 2.2 ng/mL in Jan 2023 to 3.7 ng/mL in Jan 2025.
The EAU guideline suggests omitting biopsy when PSA density is below $0.20 \text{ ng/mL/cc}$, which is met with a value of $0.07 \text{ ng/mL}^2$.
Findings that argue AGAINST sampling this patient now:
The mpMRI shows a PI-RADS score of 2, which aligns with the cohort criterion for deferral.
The EAU guideline suggests omitting biopsy when MRI is negative (PI-RADS $\le 2$).

WHERE THIS LEANS
The documents point towards deferral based on the PI-RADS 2 score and the low PSA density, which aligns with the cohort criterion.
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 3.70 ng/mL over 4 points spanning 24 months; velocity +0.75 ng/mL per year; doubling time about 32 months.
PROJECTION at 6 months: 4.5 ng/mL, conformal 95% band 1.3-15.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.33
  uncertainty  +/- 0.11 epistemic (95% band 0.10-0.55), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 56% of the time over the 25 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.28  ('supports' tier)
  EXPERT-FUSION      DEFER, p(biopsy)=0.33  ('supports' tier, fusion_nolab)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.00  (k=3 precedents)
  EXPERT-COHORT      DEFER  (rule pirads_le_2)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_le_2) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 24 of 24 labelled cases in exactly this situation (never biopsied).

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, and previous_notes—directly address all three moderator questions.

ALIGNMENT WITH THE PANEL
The retrieved evidence, specifically the PI-RADS 2 score from the panel and the PSA density of $0.07 \text{ ng/mL}^2$ (which the EAU guideline supports for deferral), aligns with the PANEL-PROTOCOL's answer of NO BIOPSY, which was driven by the cohort criterion ($\text{PI-RADS} \le 2$).

THE OPEN QUESTIONS, ONE BY ONE
Q1. The radiology_report states the lesion is "An 8 mm nodule within the right mid-transition zone exhibits T2 hyperintensity without diffusion restriction."
Q2. The psa_trend shows a serial PSA value trend: {"date": "Jan 2023", "val": 2.2}, {"date": "Sep 2023", "val": 2.6}, {"date": "May 2024", "val": 3.1}, {"date": "Jan 2025", "val": 3.7}.
Q3. The previous_notes indicate "Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)" and the context was a referral for mpMRI evaluation.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS score of 2 is highly weighted because the EXPERT-COHORT explicitly matched the reading urologist in 24 of 24 cases for this specific finding, providing strong cohort support for deferral. The low PSA density ($0.07 \text{ ng/mL}^2$) is also critical as it aligns with the EAU guideline suggesting omission when this value is low.

MY SUGGESTION TO THE CHAIR
I suggest deferral based on the strong alignment between the PI-RADS 2 finding, the low PSA density, and the cohort data, which supports the PANEL-PROTOCOL's conclusion.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The decision to defer biopsy is supported by the cohort criterion, which matched the reading urologist in 24 of 24 cases where the PI-RADS score was 2 or less. This is further reinforced by the low PSA density of 0.07 ng/mL^2, which aligns with EAU guidelines for omission when the MRI is negative. The evidence converged on deferral, as the PI-RADS 2 finding and low PSA density outweighed the rising PSA trajectory.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
